Bristol-Myers Squibb Company (BMY) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1101221083

(NYSE:BMY Stock) Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New York. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Bristol-Myers Squibb Company (BMY) - Stock & Dividends

BMY Stock Overview

Market Cap in USD 99,977m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1972-01-01

BMY Stock Ratings

Fundamental 6.43
Dividend 8.09
Growth 5y 1.13
Rel. Performance vs Sector -4.34
Analysts 3.41
Fair Price Total Ret. 52.38
Fair Price DCF 168.13

BMY Dividends

Yield 12m 4.63%
Yield on Cost 5y 5.34%
Dividends CAGR 5y 6.81%
Payout Consistency 94.3%

BMY Growth Ratios

Growth 12m -27.23%
Growth Correlation 12m -82%
Growth Correlation 3m -4%
CAGR 5y 2.89%
CAGR / Mean Drawdown 0.27
Sharpe Ratio 12m -1.71
Alpha vs SP500 12m -46.02
Beta vs SP500 5y weekly 0.64
CAPM 7.00%
Average Daily Range 2m 2.10%
Regime Oscillator 85.47
Volatility GJR Garch 1y 21.27%
Price / SMA 50 -0.62%
Price / SMA 200 -11.69%
Current Volume 13778.7k
Average Volume 20d 15544.7k
What is the price of BMY stocks?
As of February 21, 2024, the stock is trading at USD 49.86 with a total of 13,778,740 shares traded.
Over the past week, the price has changed by +2.36%, over one month by -0.50%, over three months by +3.15% and over the past year by -27.23%.
Why is BMY stock down?
Check with which Index or Commodity BMY has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return BMY Return S&P 500
1 Month -0.50% 2.97%
3 Months 3.15% 9.80%
12 Months -27.23% 26.37%
What is the forecast for BMY stock price target?
According to ValueRays Forecast Model, BMY Bristol-Myers Squibb Company will be worth about 56.6 in February 2025.
Issuer Forecast Upside
Wallstreet Target Price 56.6 13.4%
Analysts Target Price 71.6 43.5%
ValueRay Target Price 56.6 13.5%